An Evaluation of Wuhan Volume-based Procurement of Insulin in 2019
Objective To evaluate Wuhan volume-based procurement(VBP)of insulin in 2019,including the impact on the insulin market share in Wuhan,the usage of insulin in medical institutions in Wuhan and the inspiration for the scheme design of national VBP of insulin in 2021.Methods Data of insulin procurement in 2018 and 2020 were obtained from Wuhan Municipal Healthcare Security Administration.The changes of insulin market share and insulin product prices before and after the VBP in Wuhan in 2019 were analyzed.The conversion of insulin after the VBP were analyzed based on interviews with 8 endocrinologists,pharmacy department directors and medical quality con-trol personnel from 7 medical institutions.Results The average price of insulin products in Wuhan decreased 5.67％after the VBP.The average price decrease of local brands was 8.39％while the average price decrease of imported drugs was 5.05％.The insulin market was still dominated by multinational companies.Thus,the conversion on use of insulin drugs in Wuhan was actually rare.Clinicians are cautious about this kind of conversion,while special trai-ning for clinicians for such conversion is extremely rare.Conclusion Although the VBP of insulin in Wuhan has achieved a certain price reduction effect,it's arduous to stimulate large-scale price reduction of insulin due to limited market size.However,as the first city piloting the VBP of biologics in China,the VBP of insulin in Wuhan in 2019 proved the feasibility of VBPs on biologics,and provided certain experience and lessons for national VBP of insulin in 2021.
NETL
NSTL
万方数据
